This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
JAZZ or CTLT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
JAZZ vs. CTLT: Which Stock Is the Better Value Option?
5 High ROE Stocks to Buy as Volatility Weighs on Markets
by Supriyo Bose
DIS, LDOS, RF, FTNT and JAZZ are some of the stocks with high ROE to profit from as intense volatility spooks markets.
Jazz (JAZZ) Up 3.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wall Street Analysts Think Jazz (JAZZ) Could Surge 44.37%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 44.4% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ChromaDex Corporation (CDXC) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
ChromaDex (CDXC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More
by Zacks Equity Research
SAGE and INCY suffer setbacks due to the failure of HD and CSU studies, respectively.
JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer
by Zacks Equity Research
Following the FDA's approval, Jazz's Ziihera becomes the first dual HER2-targeted bispecific antibody and chemotherapy-free treatment approved for biliary tract cancer.
Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is the Options Market Predicting a Spike in Jazz (JAZZ) Stock?
by Zacks Equity Research
Investors need to pay close attention to Jazz (JAZZ) stock based on the movements in the options market lately.
Jazz (JAZZ) Upgraded to Buy: Here's Why
by Zacks Equity Research
Jazz (JAZZ) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
JAZZ or CTLT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
JAZZ vs. CTLT: Which Stock Is the Better Value Option?
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up
by Zacks Equity Research
AXSM posts better-than-expected third-quarter results. Stock rises in response to the results and strong sales uptake of Auvelity.
Wall Street Analysts See a 37.65% Upside in Jazz (JAZZ): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Jazz (JAZZ) points to a 37.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know
by Zacks Equity Research
Explore Jazz's (JAZZ) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Jazz Tops Q3 Earnings & Sales Estimates, Raises '24 EPS View
by Zacks Equity Research
JAZZ reports better-than-expected third-quarter results. After initiating a strategic pipeline prioritization program, the company raises its EPS guidance for 2024 by 30 cents.
Compared to Estimates, Jazz (JAZZ) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of 20.84% and 1.75%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Insights Into Jazz (JAZZ) Q3: Wall Street Projections for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Jazz (JAZZ), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of 3.40% and 4.38%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More
by Zacks Equity Research
VNDA and JAZZ are in the spotlight following regulatory and pipeline updates, respectively.
Wall Street Analysts Think Jazz (JAZZ) Could Surge 51.8%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 51.8% in Jazz (JAZZ). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Are Investors Undervaluing Jazz Pharmaceuticals (JAZZ) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.